Wrays head wins opposition to MacroGenics immunotherapy patent

Intellectual Property 2019-04-04 4:05 pm | Sydney
IP Australia has ordered biotech firm MacroGenics to amend its patent for a type of polypeptide used in treatments for cancer, autoimmune disorders and other diseases after a successful opposition from the chairman of intellectual property boutique Wrays.
For information on rights and reprints, contact subscriptions@lawyerly.com.au